Vaccination in older adults: development of an educational tool, Vaxisenior, in France
- PMID: 20192713
- DOI: 10.1586/erv.10.29
Vaccination in older adults: development of an educational tool, Vaxisenior, in France
Abstract
The benefits of vaccination in older adults are well documented yet there is poor uptake of such preventive measures, and one of the main reasons in France is a lack of recommendation and support from healthcare professionals. To address this issue a multidisciplinary group of experts has developed an educational tool, Vaxisenior, to assist in the training of physicians/healthcare workers who can act as advocates for immunization programs. The tool comprises of eight sections (general introduction; immunosenescence; diphtheria-tetanus-poliomyelitis; influenza; pneumococcus; pertussis; herpes zoster; and vaccines for travelers). In addition, it includes national immunization schedules and recommendations, practical information regarding opportunities to expand vaccine coverage that is convenient to the patient and a questions and answers section covering topics relating to particular usage and responsibilities. Implementation of vaccination policies for older adults is a major issue and will require extensive promotional campaigns, as well as active support from healthcare and public health professionals to improve overall vaccine coverage.
Similar articles
-
Ensuring the willingness to vaccinate and be vaccinated.Expert Rev Vaccines. 2010 Mar;9(3 Suppl):11-4. doi: 10.1586/erv.10.28. Expert Rev Vaccines. 2010. PMID: 20192712 Review.
-
Influenza and pneumococcal vaccine coverages in geriatric health care settings in france.Gerontology. 2007;53(6):382-7. doi: 10.1159/000105166. Epub 2007 Jul 5. Gerontology. 2007. PMID: 17622768
-
Influenza vaccination coverage rates in 5 European countries: a population-based cross-sectional analysis of the seasons 02/03, 03/04 and 04/05.Infection. 2007 Oct;35(5):308-19. doi: 10.1007/s15010-007-6218-5. Epub 2007 Sep 20. Infection. 2007. PMID: 17885730
-
Herpes zoster vaccination among adults aged 60 years or older in the United States, 2007: uptake of the first new vaccine to target seniors.Vaccine. 2009 Feb 5;27(6):882-7. doi: 10.1016/j.vaccine.2008.11.077. Epub 2008 Dec 9. Vaccine. 2009. PMID: 19071175
-
Vaccination and healthy aging.Expert Rev Vaccines. 2010 Mar;9(3 Suppl):3-6. doi: 10.1586/erv.10.26. Expert Rev Vaccines. 2010. PMID: 20192710 Review.
Cited by
-
Immunogenicity and safety results from a randomized multicenter trial comparing a Tdap-IPV vaccine (REPEVAX®) and a tetanus monovalent vaccine in healthy adults: new considerations for the management of patients with tetanus-prone injuries.Hum Vaccin Immunother. 2012 Dec 1;8(12):1875-81. doi: 10.4161/hv.22083. Epub 2012 Oct 2. Hum Vaccin Immunother. 2012. PMID: 23032160 Free PMC article. Clinical Trial.
-
Strategies implemented to address vaccine hesitancy in France: A review article.Hum Vaccin Immunother. 2018 Jul 3;14(7):1580-1590. doi: 10.1080/21645515.2018.1458807. Epub 2018 Jun 14. Hum Vaccin Immunother. 2018. PMID: 29608390 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical